CoChat

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches

Open access

Abstract

A recent wave of pharmacologic and technologic innovations has revolutionized our management of retinal diseases. Many of these advancements have demonstrated efficacy and can increase the quality of life while potentially reducing complications and decreasing the burden of care for patients. Some advances, such as longer-acting anti-vascular endothelial growth factor agents, port delivery systems, gene therapy, and retinal prosthetics have been approved by the US Food and Drug Administration, and are available for clinical use. Countless other therapeutics are in various stages of development, promising a bright future for further improvements in the management of the retinal disease. Herein, we have highlighted several important novel therapies and therapeutic approaches and examine the opportunities and limitations offered by these innovations at the new frontier. KEY MESSAGESNumerous pharmacologic and technologic advancements have been emerging, providing a higher treatment efficacy while decreasing the burden and associated side effects.Anti-vascular endothelial growth factor (anti-VEGF) and its longer-acting agents have dramatically improved visual outcomes and have become a mainstay treatment in various retinal diseases.Gene therapy and retinal prosthesis implantation in the treatment of congenital retinal dystrophy can accomplish the partial restoration of vision and improved daily function in patients with blindness, an unprecedented success in the field of retina.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/07853890.2022.2066169

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Figure of the port delivery system (PDS) implant with dimensions of various components as shown. Copyright 2021 F. Hoffmann-La Roche Ltd., all rights reserved. Used with permission.
Figure 1. Figure of the port delivery system (PDS) implant with dimensions of various components as shown. Copyright 2021 F. Hoffmann-La Roche Ltd., all rights reserved. Used with permission.CC BY · PubMed Central
Figure 2. Clinical images from PDS-implanted patients. (A) In the primary position, the PDS implant is not visible through the dilated pupil. (B) In superotemporal gaze, the lower portion of the body of the implant and the release control element are visible through the dilated pupil. (C) When eye looking inferonasally, the septum of the implant is visible through the conjunctiva. Images courtesy of Dr. Arshad Khanani, Sierra Eye Associates, Reno, NV, USA.
Figure 2. Clinical images from PDS-implanted patients. (A) In the primary position, the PDS implant is not visible through the dilated pupil. (B) In superotemporal gaze, the lower portion of the body of the implant and the release control element are visible through the dilated pupil. (C) When eye looking inferonasally, the septum of the implant is visible through the conjunctiva. Images courtesy of Dr. Arshad Khanani, Sierra Eye Associates, Reno, NV, USA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Cited by

See all 20

Metadata

Authors
Nanegrungsunk, O., Au, A., Sarraf, D., & Sadda, S. R.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Sadda, Srinivas R.
Venue
Annals of Medicine
Published
2022-04-25
Volume
54
Issue
1
Pages
1067-1080
ISSN
  • 0785-3890 (ISSN-L)
  • 1365-2060
OpenAlex
W4224823375
Cited by
20
References
100
Citations by year
2026: 4 · 2025: 7 · 2024: 3 · 2023: 4 · 2022: 2
FWCI
0.86
Type
journal article
Language
en
Open access
Locations
  • Annals of Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
retinal disease, anti-VEGF therapy, port delivery system, gene therapy, vision restoration, retinal drug delivery, new drugs
MeSH terms
Humans, Quality of Life, Retina, Retinal Diseases, United States, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches. https://app.cochat.ai/papers/10.1080/07853890.2022.2066169
The paper
Nanegrungsunk, O., Au, A., Sarraf, D., & Sadda, S. R. (2022). New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches. Annals of Medicine. https://doi.org/10.1080/07853890.2022.2066169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.